Primary tumor location as a prognostic factor in metastatic colorectal cancer.

ABSTRACT:

Background

We sought to clarify the prognostic impact of primary tumor location in metastatic colorectal cancer (mCRC).

Methods

We evaluated the association between tumor location and survival parameters in patients with previously untreated mCRC receiving first-line chemotherapy ± bevacizumab in three independent cohorts: a prospective pharmacogenetic study (PROVETTA) and two randomized phase III trials, AVF2107g and NO16966. Cancers proximal or distal of the splenic flexure were classified as right-sided or left-sided, respectively. The primary end point was overall survival (OS). Data were analyzed with Cox proportional hazards and logistic regression models. All statistical tests were two-sided.

Results

Among evaluable patients in the PROVETTA (n = 200), AVF2107g

SUBMITTER: Loupakis F 

PROVIDER: S-EPMC4565528 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature